SEC EDGARSEP 241 min read$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $29K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 800 shares of Pharvaris N.V. (PHVS) at $36.19 on 2026-09-22.

Original reporting

SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus

Published Sep 24, 2026, 2:43 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 24, 2026, 2:55 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$PHVS

Neutral

high confidence

Mentioned

$PHVS

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$PHVSNeutralLow

Why it matters

The disclosed sale is modest and does not suggest a change in insider confidence.

Market read

Small insider sale; limited relevance for traders.

Timing

filing date 2026-09-24

Relevance 3/10Novelty 4/10Timing: filing date 2026-09-24

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHVSNeutralHigh confidence

Context

Director Schikan sold 800 shares for $28,952, reducing his holdings to 115,167 shares.

Expected impact

minimal impact, price likely unchanged

Evidence & confidence

Sale size is small relative to float and no broader market implications.

Key entities

company
Pharvaris N.V.
Biotech company listed on Nasdaq under ticker PHVS.
person
Schikan Johannes Gerardus Christiaan Petrus
Director of Pharvaris who sold shares.

Read at source ← All news

OCT 26

$PHVSHighAI 9/10

Bank of America backs Pharvaris on breakthrough for rare swelling disease

Bank of America upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing strong trial results for its HAE treatment drug, deucrictibant. The stock closed at $31.41 on Oct. 23. BofA sees substantial upside and notes positive feedback from doctors. The FDA decisions in 2027 could impact the stock.

finance.yahoo.com2 min

OCT 23

$PHVSMed

Pharvaris rises after BofA upgrades to Buy (PHVS:NASDAQ)

Pharvaris (PHVS) shares rose 3% premarket after BofA upgraded the stock to Buy from Neutral, citing its oral HAE potential. The brokerage kept its $44 price target. Pharvaris announced in September its.

seekingalpha.com1 min

OCT 23

$PHVSHigh

BofA upgrades Pharvaris stock rating on oral HAE treatment potential

BofA upgraded Pharvaris (PHVS) to Buy with a $44 price target, citing potential in its oral HAE treatment. The stock trades at $30.68, up 10.6% in a week. Positive phase 3 data and strong analyst ratings highlight its prospects, despite risks like market adoption and competition.

investing.com1 min

OCT 9

$PHVSHighAI 9/10

Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027

Pharvaris (PHVS) reported that its Phase 3 study of deucrictibant XR for hereditary angioedema (HAE) met all endpoints, reducing attack rates by 83%. The company plans to file for FDA approval in H1 2027. PHVS stock closed at $31.12, up 0.58% in after-hours trading.

rttnews.com3 min

OCT 8

$PHVSMedAI 8/10

Pharvaris HAE drug shows faster symptom relief in Lancet study

Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.

investing.com5 min